Table 8. Characteristics of studies included in the systematic review on the impact of PCa on T2DM control and treatments.

Author, year, country	Study design	No. of patients	Main outcomes	Main findings
Keating, 2014, USA [81]	Cohort with propensity matching	2237 pairs of propensity matched men with PCa and T2DM who were or were not treated with ADT	The effect of ADT onT2DM control, as measured by HbA1c levels and the intensification of T2DM drug therapy.	HbA1c increased at 1 year for men treated with ADT (7.38 from 7.24 p value 0.04) Receipt of ADT was also associated with an increased risk of addition of T2DM medication (HR 1.20 95% CI: 1.09–1.32)
Rowbottom, 2015, Canada [83]	Cohort	30 GU Cancer patients: 26 PCa 4Bladder Ca	Change in T2DM management or hospitalisation due to T2DM in those receiving corticosteroids with chemotherapy	40% required a change in their diabetes management (n = 4) 20% (n = 2) required hospitalisations
Derweesh, 2007, USA [82]	Cohort	77 patients	To assess worsening glycaemic control in men with established T2DM after starting ADT for PCa	An increase of ≥ 10% in serum HbA1c in 15 patients (19.5%)An increase of ≥ 10% in FBG in 22 patients (28.6%)